Skipping the slow climb: Omalizumab paves a faster path to food allergy OIT

A new prospective study published in Annals of Allergy, Asthma & Immunology shows that a brief pretreatment course of omalizumab (Xolair) can dramatically streamline oral immunotherapy (OIT) for food-allergic patients. In a cohort of 100 children and young adults (median age 9), those who received at least 8 weeks of omalizumab before OIT were able to skip the traditional multi-step dose escalation process — jumping directly to low maintenance doses after just a two-dose initiation challenge.

The results were striking: 97% of patients started daily OIT maintenance dosing for at least one food allergen, and 84% started at target doses for all their allergens. The simplified protocol cut the typical 10–11 clinic visits needed to reach maintenance down to just 1–2 visits.

By the Numbers

• 94% of initiation challenges were tolerated without dose-limiting symptoms
• 84% of patients started at target maintenance doses for all foods
• 40% experienced an adverse event (most commonly abdominal pain or oral pruritus)
• Only 2% discontinued therapy due to adverse events
• 6% received epinephrine during the study period

Why it matters: Traditional OIT is burdensome — requiring frequent clinic visits over months. This omalizumab-facilitated protocol offers a faster, more tolerable path to food allergy protection, which could meaningfully improve access and adherence for families. Longer-term follow-up studies are still needed to confirm durability.